Evidence map›Paper›PMID 39579150›Full record

ArticleMolecular pharmaceutics2025

Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity.

Changkeun Im, Jae Hun Ahn, Hwisoo Lim, Dohyeon Kim, Yong Jin Lee, Chi Soo Kang, Choong Mo Kang

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Theranostic Application of Radiohalogens in Nuclear Medicine.Nuclear medicine and molecular imaging · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Changkeun ImDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Jae Hun AhnDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.ORCID 0009-0001-3339-5825
Hwisoo LimDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Dohyeon KimDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Yong Jin LeeDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.ORCID 0000-0002-7140-354X
Chi Soo KangDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Choong Mo KangDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.ORCID 0009-0000-1474-4447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioiodine has been exploited in nuclear medicine for diagnostic and therapeutic purposes in various diseases. There are two radioiodination methods for biomolecules, that is, (1) direct radioiodination of tyrosine or histidine residue in a biomolecule and (2) indirect radioiodination by using a prosthetic group, which bridges radioiodine and the biomolecule. While directly radioiodinated biomolecules suffer from deiodination

Indexed as

Aza CompoundsBenzene DerivativesCross-Linking ReagentsRadiopharmaceuticalsTrastuzumabAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansIodine RadioisotopesMiceMice, Inbred BALB CAza CompoundsBenzene DerivativesCross-Linking ReagentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIodine RadioisotopesRadiopharmaceuticalsTrastuzumabfluorous solid-phase extractionHER2prosthetic click-linkerradioiodination

Identifiers

PMID39579150
PMCPMC11707743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.